Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Diabetes. Aug 15, 2026; 17(8): 123635
Published online Aug 15, 2026. doi: 10.4239/wjd.123635
Published online Aug 15, 2026. doi: 10.4239/wjd.123635
Expression and clinical value of the plasma peroxiredoxin family in early pregnancy for predicting subsequent gestational diabetes mellitus
Xiao-Peng Xu, Zhou Zhang, Chen Qian, Department of Clinical Laboratory, Central Laboratory, Xishan People’s Hospital of Wuxi City, Wuxi 214105, Jiangsu Province, China
Shun Ding, Department of Clinical Laboratory, The 904th Hospital of Joint Logistic Support Force of PLA, Wuxi 214000, Jiangsu Province, China
Yan-Mei Che, Department of Obstetrics and Gynecology, Xishan People’s Hospital of Wuxi City, Wuxi 214105, Jiangsu Province, China
Jing Li, Department of Endocrinology, Jiangsu Province (Suqian) Hospital, Suqian 223800, Jiangsu Province, China
Co-corresponding authors: Zhou Zhang and Chen Qian.
Author contributions: Xu XP and Qian C were responsible for experiment conception and design; Ding S and Che YM carried out the experiments; Xu XP, Zhang Z, and Li J participated in data analysis; Xu XP, Zhang Z, Li J, and Qian C drafted the paper; Zhang Z and Qian C contributed equally as co-corresponding authors. All authors have read and approved the final manuscript to be published.
AI contribution statement: The authors take full responsibility and accountability for all content of this manuscript, including any portions for which AI tools were used as assistive technologies. All AI-assisted outputs were carefully reviewed, validated, and approved by the authors. AI tools were not used to generate original scientific data, perform independent scientific analyses, or draw scientific conclusions.
Supported by Scientific Research Program of Wuxi Health Commission, No. Z202515; and Youth Innovation Cultivation Program of Xishan People’s Hospital, No. 202104.
Institutional review board statement: This study obtained approval from the Ethics Committee of Xishan People’s Hospital of Wuxi City, No. xs2024ky050.
Informed consent statement: Verbal informed consent was obtained from all patients prior to the use of their stored samples and clinical data.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: All data can be obtained upon reasonable request from the corresponding author.
Corresponding author: Chen Qian, Chief Technologist, Department of Clinical Laboratory, Central Laboratory, Xishan People’s Hospital of Wuxi City, No. 1128 Dacheng Road, Wuxi 214105, Jiangsu Province, China. qianchenwxxs@163.com
Received: May 25, 2026
Revised: June 10, 2026
Accepted: July 2, 2026
Published online: August 15, 2026
Processing time: 73 Days and 16.6 Hours
Revised: June 10, 2026
Accepted: July 2, 2026
Published online: August 15, 2026
Processing time: 73 Days and 16.6 Hours
Core Tip
Core Tip: This study provides the first comprehensive assessment of the plasma peroxiredoxin (PRDX) family in early pregnancy as predictive biomarkers for gestational diabetes mellitus. PRDX1, PRDX4, and PRDX5 demonstrated strong individual diagnostic performance (areas under the curve: 0.757, 0.776, and 0.742, respectively), and their combination further improved accuracy to 0.836. Furthermore, PRDX1 and PRDX3 were identified as independent risk factors for early gestational diabetes mellitus, highlighting the potential of the PRDX family for early screening and risk stratification.